600161.SS SHH
Beijing Tiantan Biological Products Co., Ltd.
1W: +1.9%
1M: +2.9%
3M: +4.7%
YTD: -23.7%
1Y: -37.9%
3Y: -38.6%
5Y: -43.0%
¥12.59 ($1.88)
+0.47 (+3.88%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Cash Flow Trends
Operating Cash Flow
$376M
-54.1% ▼
5Y CAGR: -11.7%
Capital Expenditures
$606M
+43.3% ▲
5Y CAGR: -0.1%
Free Cash Flow
-$230M
+7.3% ▲
Dividends Paid
$494M
-100.0% ▼
Buybacks
$0
+0.0% ▲
Net Change in Cash
$563M
+139.9% ▲
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | $1.1B | $1.2B | $1.5B | $2.1B | $1.1B |
| Depreciation & Amort. | $157M | $180M | $268M | $332M | $454M |
| Stock-Based Comp. | $0 | $0 | $0 | $0 | $0 |
| Change in Working Capital | -$262M | -$234M | $614M | -$1.7B | -$1.7B |
| Other Non-Cash Items | $16M | -$24M | $2M | $42M | $506M |
| Operating Cash Flow | $980M | $1.1B | $2.4B | $820M | $376M |
| — Investing Activities — | |||||
| Capital Expenditures | -$1.1B | -$1.4B | -$1.1B | -$1.1B | -$606M |
| Acquisitions (Net) | -$29M | -$36M | -$2M | -$964M | -$2M |
| Investment Purchases | -$30M | -$1.5B | $0 | $0 | -$15M |
| Investment Sales | $9M | $22M | $34M | $47M | $709M |
| Other Investing | -$1.0B | $997M | -$235M | $125M | $0 |
| Investing Cash Flow | -$2.2B | -$1.9B | -$1.3B | -$1.9B | $87M |
| — Financing Activities — | |||||
| Net Debt Issuance | -$326M | -$108M | -$366M | -$18M | $287M |
| Stock Repurchased | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | -$137M | -$137M | -$82M | -$247M | -$494M |
| Other Financing | $3.3B | -$113M | -$59M | -$105M | -$235M |
| Financing Cash Flow | $2.8B | -$378M | -$508M | -$370M | -$442M |
| Net Change in Cash | $1.6B | -$1.1B | $639M | -$1.4B | $563M |
| Cash End of Period | $3.3B | $2.2B | $2.8B | $1.4B | $2.0B |
| Free Cash Flow | -$151M | -$228M | $1.3B | -$248M | -$230M |